2
Clinical Trials associated with Romiplostim biosimilar (Generium ZAO)Extension Study of Long-term Safety and Immunogenicity of GNR-069 Patients With Idiopathic Thrombocytopenic Purpura Who Completed Phase 3 RMP-ITP-III Clinical Trial
It is a phase III extension study to assess safety and immunogenicity of long-term therapy with GNR-069 in patients with idiopathic thrombocytopenic purpura
Multicenter Randomized Double-blind Comparative Study of Clinical Efficacy and Safety of GNR-069 (JSC "GENERIUM", Russia) and Nplate (Amgen Europe BV, The Netherlands) in Patients With Idiopathic Thrombocytopenic Purpura
It is a phase III multicenter randomized double-blinded comparative study of clinical efficacy and safety of GNR-069 and Nplate in patients with idiopathic thrombocytopenic purpura
100 Clinical Results associated with Romiplostim biosimilar (Generium ZAO)
100 Translational Medicine associated with Romiplostim biosimilar (Generium ZAO)
100 Patents (Medical) associated with Romiplostim biosimilar (Generium ZAO)
100 Deals associated with Romiplostim biosimilar (Generium ZAO)